Gregory Crimmins, founder and CEO of Remedy Plan Therapeutics, discusses the role of NAMPT in cancer, the challenges of developing NAMPT inhibitors without toxicity, and why he believes the company has solved the problem. https://lnkd.in/gxdE4_hU
Levine Media Group’s Post
More Relevant Posts
-
More than a dozen PARP1 selective drugs in different stages development presented at the American Association for Cancer Research #AACR24 ! Should we consider them 2nd generation PARP inhibitors or a completely NEW class of drugs? 👉🏼Selective PARP1 inhibitors /PARP1-based dual-target inhibitors/PROTAC PARP1 degraders/ prodrugs of PARP1 inhibitors
-
-
The first clinical data for casdatifan, our HIF-2a inhibitor for the treatment of #kidneycancer, will be presented in an oral plenary session at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Read more about this news and the posters we’ll be presenting: https://bit.ly/3YeEM5Y #ENASymp24
-
-
Download this new poster for an insight into glycan-protein interactions! Learn how heparan sulfate (HS) and chondroitin sulfate (CS) influence everything from cell migration to cancer metastasis. Discover how Glycan Therapeutics can provide you with the tools needed to delve into carbohydrate-protein interactions! >>> https://hubs.ly/Q02JbQ_H0
-
Our latest article explores how LC-MS/MS revolutionizes the analysis of antibody-drug conjugates (ADCs), offering a perfect blend of precision, speed, and cost savings. Learn how this method stands out in the fast-paced world of cancer therapeutics. #ADCDrugs #LCMS #BioassayOptimization #DrugDevelopment #CancerResearch https://hubs.li/Q02JGgl-0
-
-
Download this new poster for an insight into glycan-protein interactions! Learn how heparan sulfate (HS) and chondroitin sulfate (CS) influence everything from cell migration to cancer metastasis. Discover how Glycan Therapeutics can provide you with the tools needed to delve into carbohydrate-protein interactions! >>> https://hubs.ly/Q02Hpkn60
Poster: Construction of structurally defined heparan sulfate and chondroitin sulfate microarrays
-
Our latest article explores how LC-MS/MS revolutionizes the analysis of antibody-drug conjugates (ADCs), offering a perfect blend of precision, speed, and cost savings. Learn how this method stands out in the fast-paced world of cancer therapeutics. #ADCDrugs #LCMS #BioassayOptimization #DrugDevelopment #CancerResearch https://hubs.li/Q02JGh3P0
-
-
Learn more on cancer cachexia complexities: Elevated P-selectin in cancer patients may contribute to inflammation, muscle atrophy, & hypercoagulation. Delve into P-selectin inhibitors as promising therapeutics. Read more - https://ow.ly/q2WH50QwQmA #CancerResearch #Inflammation
-
Watch our webinar with Amplia Therapeutics Limited, featuring CEO and MD Chris Burns. The webinar will commence with a presentation, followed by a live Q&A with the audience, providing you the opportunity to ask Chris any questions about ATX that you may have. Key topics: - Data from recent trial - Why ovarian and pancreatic cancer? - What are the next key milestones and value drivers? - Where were the drugs discovered? Register here: https://hubs.la/Q02zctXZ0
-
-
Did you know that the myTRIAList trial finder includes trial overview videos, like the MOUNTAINEER-03 trial, that feature investigator testimonies and plain language summaries that explain the trial to people living with cancer and their caregivers? Check out the trial finder to learn more about cancer clinical trials here: https://buff.ly/3XelQE7 #colorectalcancer #oncology #pharma #biotech #clinicaltrials CancerCare
-
-
Another exiting news from Ryvu Therapeutics straight from #AACR24! Our latest research on WRN inhibitors allowed progressing lead molecules to in vivo studies, which confirmed robust efficacy of Ryvu’s WRN inhibitors in MSI-H xenograft cancer models. #NewTargets #WRN #syntheticlethality
-
